You are here: Industry Insights > GSK

News List

UK Biobank attracts backing from GSK and Regeneron pharmatimes
March 27, 2017
GlaxoSmithKline and Regeneron have given their backing to a new project that will use patient data held by the UK Biobank.
GSK starts $175M plant to boost production of vaccine star Bexsero fiercepharma
March 23, 2017
Vaccines have been one of the financial bright spots for GlaxoSmithKline and Bexsero, which it picked up in its asset swap with Novartis, has had stellar sales. To boost both, GSK is building a $175 million plant in Germany so it can expand production of
GSK Seeks Expanded Indication for Fluarix® Quadrivalent for Infants Six Months and Older americanpharmaceuticalreview
March 17, 2017
GSK has announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for FLUARIX® QUADRIVALENT (Influenza Vaccine).
GSK Consumer Healthcare launches new toothpaste in the US specifically formulated for gum health cphi-online
March 15, 2017
parodontax - first toothpaste proven to help consumers leave bleeding gums behind.
GSK consolidates DT and TT vax production in Hungary plant, adding 100 jobs fiercepharma
March 14, 2017
With GlaxoSmithKline’s vaccines sales expanding, it figures it needs expanded production as well and some of that will happen at a 10-year-old plant in Hungary as well as Germany.
GSK study shows Nucala significantly improves quality of life and lung function in severe asthma pat cphi-online
March 08, 2017
Provides hope for patients with severe asthma, who currently have very limited treatment options.
GSK's vaccines access leads the pack, report says, as lagging Pfizer disputes findings fiercepharma
March 08, 2017
For the first time, the public health watchdogs at the Access to Medicine Foundation have trained their microscopes specifically on vaccines and the companies that make them.
GSK confirms closure of agreement to divest anaesthesia portfolio to Aspen firstwordpharma
March 02, 2017
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the closure of an agreement with Aspen (JSE: APN) aligned with GSK's strategy of simplification through focusing on core therapeutic areas.
Vectura achieves £9 million royalty cap from GSK Ellipta products cphi-online
February 21, 2017
Company achieves the £9 million calendar year royalty cap on net sales of Ellipta products a year earlier than previously guided.
Witty's bet on vaccines pays off in GSK CEO's final full year fiercepharma
February 13, 2017
After nearly 10 years at the CEO post for GlaxoSmithKline, Andrew Witty is handing over the reins to a company that has been reshaped with a vaccines focus. And during Witty’s final full year at the drugmaker, that business segment outgrew each of GSK’s o

Previous page 1 2 3 4 5 6 7 8 9 10 ... 40 41 Next page